Ribo Receives Phase II Clinical Approval for ApoC3-targeting siRNA drug RBD5044 in China
Suzhou Ribo Life Science Co., Ltd. (“Ribo” or the “Company”, stock code: 06938.HK) announced that its internally developed siRNA therapeutic targeting ApoC3, RBD5044, has received Investigational New Drug (IND) approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical trial as of January 22nd 2026.
RBD5044 is a GalNAc conjugated siRNA designed using the company’s proprietary RiboGalSTARTM liver targeting technology platform for the treatment of hypertriglyceridemia. It is the second ApoC3-targeting siRNA worldwide to enter clinical development. In the Phase I clinical trial, a single injection of RBD5044 resulted in up to an 84% reduction in ApoC3, accompanied by a triglyceride (TG) reduction of up to 70%, which remained below 50% of baseline at the six months follow-up. Participants also demonstrated a broadly improved lipid profile. The therapy was well tolerated, with no dose dependent adverse events and no liver enzyme elevations observed at the highest dose tested. Together, these safety and efficacy findings support RBD5044’s potential as a best-in-class ApoC3-targeting therapy.
In October 2024, the program received Phase II clinical trial approval from the European Medicines Agency (EMA), and the study is currently ongoing in patients with mixed dyslipidemia in Sweden. Supported by the NMPA’s “Announcement on Optimizing the Review and Approval of Clinical Trials for Innovative Drugs”, the product qualified for the 30workingday fast track review, resulting in a successful approval.
Ribo will now accelerate the Phase II clinical development of RBD5044 in China, with the aim of delivering more precise, durable, and safe siRNA treatment options for patients with hypertriglyceridemia as quickly as possible.